Precipio (NASDAQ:PRPO) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?

Precipio, Inc. (NASDAQ:PRPO) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $25.23 and traded as low as $22.75. Precipio shares last traded at $23.00, with a volume of 39,318 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on PRPO shares. Wall Street Zen lowered Precipio from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Precipio has an average rating of “Sell”.

Precipio Stock Performance

The company has a quick ratio of 1.33, a current ratio of 1.56 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $41.17 million, a P/E ratio of -48.94 and a beta of 1.30. The stock has a fifty day moving average of $26.68 and a 200-day moving average of $25.23.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter. The firm had revenue of $6.71 million for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP bought a new position in shares of Precipio during the third quarter worth about $194,000. Renaissance Technologies LLC grew its holdings in shares of Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after buying an additional 1,400 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after buying an additional 789 shares in the last quarter. Evernest Financial Advisors LLC bought a new position in shares of Precipio during the third quarter worth about $374,000. Finally, Topline Capital Management LLC bought a new position in shares of Precipio during the third quarter worth about $1,158,000. 10.45% of the stock is currently owned by institutional investors.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.